Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002509 · ClinicalTrials.gov registry record · Phase 1
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
A Phase 1 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002509 is a Phase 1 study that has completed, run by Temple University.
The verdict
NCT00002509, a Phase 1 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemotherapy followed by peripheral stem cell transplantation or autologous bone marrow transplantation in women with stage II breast cancer with eight or more positive axillary lymph nodes and in women with stage III or metastatic breast cancer.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG mesna
Trial Details
| Field | Value |
|---|---|
| Start Date | 1991-11 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002509
The ClinicalTrials.gov registry entry for NCT00002509 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00002509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002509 about?
NCT00002509 is a clinical study titled "High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination ...
What is the current status of trial NCT00002509?
This trial is currently completed. It is a Phase 1 study. The study started on 1991-11. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00002509?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), mesna (DRUG).
Who is sponsoring clinical trial NCT00002509?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.